Health & Fitness
Fri, September 25, 2009Thu, September 24, 2009Wed, September 23, 2009Tue, September 22, 2009Mon, September 21, 2009Fri, September 18, 2009Thu, September 17, 2009Wed, September 16, 2009Tue, September 15, 2009Mon, September 14, 2009Fri, September 11, 2009Thu, September 10, 2009Wed, September 9, 2009Tue, September 8, 2009Sun, September 6, 2009Fri, September 4, 2009Thu, September 3, 2009Wed, September 2, 2009Tue, September 1, 2009Mon, August 31, 2009Fri, August 28, 2009Thu, August 27, 2009Wed, August 26, 2009Tue, August 25, 2009Mon, August 24, 2009Sun, August 23, 2009Fri, August 21, 2009Thu, August 20, 2009Wed, August 19, 2009Tue, August 18, 2009Mon, August 17, 2009Sun, August 16, 2009Fri, August 14, 2009Thu, August 13, 2009Wed, August 12, 2009Tue, August 11, 2009Mon, August 10, 2009Fri, August 7, 2009Thu, August 6, 2009Wed, August 5, 2009Tue, August 4, 2009Corporate Profile, LLC: Access Pharmaceuticals CEO Interviewed on CorporateProfile.com
//health-fitness.news-articles.net/content/2009/ .. als-ceo-interviewed-on-corporateprofile-com.html
Published in Health and Fitness on Tuesday, September 1st 2009 at 5:16 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
NEW YORK, NY--(Marketwire - September 1, 2009) - Corporate Profile, LLC announced today that Access Pharmaceuticals, Inc. (
The video can be viewed at: [ www.corporateprofile.com ].
About Access Pharmaceuticals
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
For additional information, please visit [ www.accesspharma.com ].
About CorporateProfile.com
CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in the unique platform for investors to receive today's hottest tips and market info.
From New York's top models straight to Wall Street, Corporate Profile's financial models are on the street and in the markets, interviewing CEOs, investment managers, and market gurus about what really drives returns.
Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.
